Cytochrome P450 Enzymes as Drug Targets in Human Disease
- 4 October 2023
- journal article
- review article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 52 (6) , 493-497
Abstract
Although the mention of cytochrome P450 (P450, CYP) inhibition usually brings to mind unwanted variability in pharmacokinetics, in several cases P450s are good targets for inhibition. These P450s are essential but in certain disease states it is desirable to reduce the concentrations of their products. Most of the attention to date has been with human P450s 5A1, 11A1, 11B1, 11B2, 17A1, 19A1, and 51A1. In some of those cases, there are multiple drugs in us, e.g., exemestane, letrozole, and anastrozole with P450 19A1, the steroid aromatase target in breast cancer. There are also several targets that are less developed, e. g. P450s 2A6, 8B1, 4A11, 24A1, 26A1, and 26B1. Significance Statement The selective inhibition of certain P450s that have major physiological functions has been shown to be very efficacious in certain human diseases. In several cases the search for better drugs continues.Keywords
This publication has 49 references indexed in Scilit:
- Nirmatrelvir Plus Ritonavir: First ApprovalDrugs, 2022
- Pharmacokinetics and Pharmacodynamics of PosaconazoleDrugs, 2020
- Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertensionBioorganic & Medicinal Chemistry Letters, 2017
- 4-Anilino-pyrimidine, novel aldosterone synthase (CYP11B2) inhibitors bearing pyrimidine structuresBioorganic & Medicinal Chemistry Letters, 2017
- Posaconazole (Noxafil, SCH 56592), a new azole antifungal drug, was a discovery based on the isolation and mass spectral characterization of a circulating metabolite of an earlier lead (SCH 51048)Journal of Mass Spectrometry, 2007
- Sterol 14α-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdomsBiochimica et Biophysica Acta (BBA) - General Subjects, 2007
- Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5]Bioorganic & Medicinal Chemistry Letters, 2006
- The Diagnosis of Cushing's SyndromeArchives of internal medicine (1960), 2000
- Aromatase inhibitors and hormone-dependent cancersThe Journal of Steroid Biochemistry and Molecular Biology, 1990
- Modified acetylenic steroids as potent mechanism-based inhibitors of cytochrome P-450SCCThe Journal of Steroid Biochemistry and Molecular Biology, 1990